From Targeted Science to Better Healthcare™
Clinical Data is a global biotechnology company developing early and late stage targeted therapeutics as well as genetic and pharmacogenomic tests that detect serious diseases and help predict drug safety, tolerability and efficacy. Our late-stage compounds include: Vilazodone, a potential first-in-class drug candidate for the treatment of depression, and Stedivaze™, a potential best-in-class cardiac stress agent. By employing biomarker strategies and technologies to develop targeted therapeutics with potential advantages over currently available treatments, thus, offering tangible benefits for patients, healthcare professionals and payers.
The Company’s PGxHealth division is further leveraging its biomarker discovery expertise and intellectual property to develop and commercialize pharmacogenomic tests to detect serious diseases and help predict drug safety, tolerability and efficacy. PGxHealth has built the commercial, managed care and CLIA-certified laboratory infrastructure and capabilities to support our currently marketed tests including the FAMILION® family of genetic tests for inherited heart diseases and PGxPredict™ tests for predicting drug response. |
